Bristol-Myers Squibb Co. (NYSE:BMY) has a beta value of 0.46 and has seen 2.83 million shares traded in the recent trading session. The company, currently valued at $100.72B, closed the recent trade at $49.68 per share which meant it lost -$1.26 on the day or -2.48% during that session. The BMY stock price is -19.32% off its 52-week high price of $59.28 and 20.79% above the 52-week low of $39.35. If we look at the company’s 10-day average daily trading volume, we find that it stood at 11.52 million shares traded. The 3-month trading volume is 13.84 million shares.
The consensus among analysts is that Bristol-Myers Squibb Co. (BMY) is Hold stock at the moment, with a recommendation rating of 2.89. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 9 out of 14 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 1.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bristol-Myers Squibb Co. (NYSE:BMY) trade information
Sporting -2.48% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BMY stock price touched $49.68 or saw a rise of 3.29%. Year-to-date, Bristol-Myers Squibb Co. shares have moved -3.18%, while the 5-day performance has seen it change -0.12%. Over the past 30 days, the shares of Bristol-Myers Squibb Co. (NYSE:BMY) have changed 2.98%. Short interest in the company has seen 22.26 million shares shorted with days to cover at 1.81.
Wall Street analysts have a consensus price target for the stock at $66.5, which means that the shares’ value could jump 25.29% from the levels at last check today. The projected low price target is $41.0 while the price target rests at a high of $85.0. In that case, then, we find that the latest price level in today’s session is -71.1% off the targeted high while a plunge would see the stock lose 17.47% from the levels at last check today.
Bristol-Myers Squibb Co. (BMY) estimates and forecasts
Figures show that Bristol-Myers Squibb Co. shares have underperformed across the wider relevant industry. The company’s shares have lost -5.46% over the past 6 months, with this year growth rate of -89.75%, compared to 17.70% for the industry. Revenue growth from the last financial year stood is estimated to be 11.30%.
16 analysts offering their estimates for the company have set an average revenue estimate of 11.3B for the current quarter. 15 have an estimated revenue figure of 11.48B for the next ending quarter. Year-ago sales stood 9.99B and 10.72B respectively for this quarter and the next, and analysts expect sales will grow by 13.10% for the current quarter and 11.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 5.14% over the past 5 years. Earnings growth for 2024 is a modest -90.05% while over the next 5 years, the company’s earnings are expected to decrease by -4.81%.
BMY Dividends
Bristol-Myers Squibb Co. is expected to release its next earnings report on 2024-Oct-31 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 2.37 at a share yield of 4.77%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 3.36%.
Bristol-Myers Squibb Co. (NYSE:BMY)’s Major holders
Insiders own 0.11% of the company shares, while shares held by institutions stand at 78.11% with a share float percentage of 78.20%. Investors are also buoyed by the number of investors in a company, with Bristol-Myers Squibb Co. having a total of 2820.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 186.57 million shares worth more than $7.75 billion. As of 2024-06-30, VANGUARD GROUP INC held 9.2225% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 158.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.59 billion and represent 7.8428% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of Jun 30, 2024, the former fund manager holds about 3.16% shares in the company for having 64.14 shares of worth $3.18 billion while later fund manager owns 52.03 shares of worth $2.58 billion as of Jun 30, 2024, which makes it owner of about 2.57% of company’s outstanding stock.
